Anti-Human CD30 Ligand-Biotin

NS0-Derived Recombinant Human CD30 Ligand Extracellular Domain (Accession # P32971)

This biotinylated antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.4 containing 50 µg of bovine serum albumin per µg of antibody with no calcium, magnesium, or preservatives present.

Lyophilized

The lyophilized, biotinylated antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for up to twelve months from date of receipt. The reconstituted biotin conjugate can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted conjugate, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Goat Anti-Human CD30 Ligand, also known as CD153 antigen recognizes Human CD30 Ligand. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

The CD30 ligand is a type II transmembrane glycoprotein of the tumor necrosis factor ligand superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. Recombinant CD30L has been shown to co-stimulate T cells and to act as a mitogen for Hodgkin's disease derived cell lines. The receptor for CD30L, CD30/ TNFRSF8/CD153, is a type I cytokine receptor that is highly expressed by activated T cells, Hodgkin and Reed- Sternberg (H-RS) cells, and anaplastic large cell lymphoma cells. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis.

1. Croager, EJ. et al. (1997) Biochim. Biophys. Acta. 1353:231
2. Gruss, HJ. et al. (1994) Blood 83:1521
3. Wendtner, CM. et al. (1995) Cancer Res. 55:4157
4. Fischer, M. et al. (2006) J. Clin. Invest. 116:2748
5. Blazar, BR. et al. (2004) J. Immunol. 173:2933